Products for Research Use Only
RegisterLogin

Epoxomicin

CAT: 0400-SIH-388-100UGSize: 100 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0400-SIH-388-100UGSize:100 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Background
Epoxomicin is a cell permeable, potent and selective proteasome inhibitor originally isolated from Actinomycetes strain based on its potent in vivo antitumor activity. It is a more potent inhibitor of the chymotrypsin-like activity of the proteasome than lactacystin. Epoxomicin also blocks trypsin-like and PGPH activities of the proteasome and regulates antigen presentation at non-toxic doses. It effectively inhibits NF-κB activation in vitro and potently blocks inflammation in vivo in the mouse ear edema assay. The ubiquitin-proteasome system (UPS) and autophagy serve as two complementary, reciprocally regulated protein degradation systems, thus inhibition of UPS by Epoxomicin activates autophagy.
Description
Proteasome inhibitor
CAS Number
134381-21-8
Product Name Alternative
N-Acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-[ (1S) -3-methyl-1-[[ (2R) -2-methyloxiranyl]carbonyl]butyl]-L-threoninamide
UNSPSC
41116105
Type
Inhibitor
Source
Synthetic
Field of Research
Cell Signaling
Purity
>95%
Weight
0.0001
Format
White solid
Solubility
Soluble in DMSO (15 mg/ml) or dichloromethane:methanol (9:1); insoluble in water.
Molecular Formula
C28H50N4O7
Molecular Weight
554.7
Precautions
Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
References & Citations
1. F. Yang, et al. (2009) Neurosci. Lett. 454: 203. 2. K. Ohkawa, et al. (2004) Int. J. Oncol. 24: 425. 3. K. Schwarz, et al. (2000) J. Immunol. 164: 6147. 4. L. Meng, et al. (1999) PNAS. 96: 10403. 5. K.B. Kim, et al. (1999) Bioorg. Med. Chem. Lett. 9: 3335. 6. N. Sin, et al. (1999) Bioorg. Med. Chem. Lett. 9: 2283. 7. M. Hanada, et al. (1992) J. Antibiot. (Tokyo) 45: 1746.

Alternative Products

CatalogName
A2606-20Epoxomicin

Popular Products